ArticleGene expression1999
LIM domain-containing protein trip6 can act as a coactivator for the v-Rel transcription factor.
Article in Gene expression, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 36 citations in OpenAlex.
- Paxillin and Kindlin: Research Progress and Biological Functions.Biomolecules · 2025Review
- Construction of an immune predictive model and identification of TRIP6 as a prognostic marker and therapeutic target of CRC by integration of single-cell and bulk RNA-seq data.Cancer immunology, immunotherapy : CII · 2024Article
- Article
- TRIP6 regulates the proliferation, migration, invasion and apoptosis of osteosarcoma cells by activating the NF-κB signaling pathway.Experimental and therapeutic medicine · 2020Article
- TRIP6 enhances stemness property of breast cancer cells through activation of Wnt/β-catenin.Cancer cell international · 2020Article
- Silencing of LIMD1 promotes proliferation and reverses cell adhesion-mediated drug resistance in non-Hodgkin's lymphoma.Oncology letters · 2019Article
- TRIP6 inhibits Hippo signaling in response to tension at adherens junctions.EMBO reports · 2018Article
- Nuclear receptors in inflammation control: repression by GR and beyond.Molecular and cellular endocrinology · 2013Review
- TRIP6: an adaptor protein that regulates cell motility, antiapoptotic signaling and transcriptional activity.Cellular signalling · 2011Review
- The adaptor protein TRIP6 antagonizes Fas-induced apoptosis but promotes its effect on cell migration.Molecular and cellular biology · 2010Article
- c-Src-mediated phosphorylation of thyroid hormone receptor-interacting protein 6 (TRIP6) promotes osteoclast sealing zone formation.The Journal of biological chemistry · 2010Article
- Regulation of the LPA2 receptor signaling through the carboxyl-terminal tail-mediated protein-protein interactions.Biochimica et biophysica acta · 2008Review
- Ajuba LIM proteins are snail/slug corepressors required for neural crest development in Xenopus.Developmental cell · 2008Article
- The LIM domain protein LPP is a coactivator for the ETS domain transcription factor PEA3.Molecular and cellular biology · 2006Article
- A nuclear isoform of the focal adhesion LIM-domain protein Trip6 integrates activating and repressing signals at AP-1- and NF-kappaB-regulated promoters.Genes & development · 2004Article
- A novel LIM protein Cal promotes cardiac differentiation by association with CSX/NKX2-5.The Journal of cell biology · 2004Article
- Multiple mutations contribute to the oncogenicity of the retroviral oncoprotein v-Rel.Oncogene · 1999Review
- [Down-regulation of TRIP6 expression induces actin cytoskeleton rearrangements in human carcinoma cell lines].Molekuliarnaia biologiiaArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
The retroviral oncoprotein v-Rel is a transcriptional activator in the Rel/NF-kappaB family of eukaryotic transcription factors. v-Rel malignantly transforms a variety of cell types in vitro and in vivo, and its transforming activity is dependent on the ability of v-Rel to bind to DNA and activate transcription. In this report, we used the yeast two-hybrid assay to identify proteins that interact with C-terminal sequences of v-Rel that are needed for transcriptional activation and transformation. One protein, Trip6, that we identified in this screen was previously identified as a thyroid hormone receptor-interacting protein. Trip6 is a member of a subfamily of LIM domain-containing proteins that are thought to transport intracellular signals from the cell surface to the nucleus. By several criteria, we show that sequences from Trip6, which include the LIM domains, behave as a coactivator for transcriptional activation by v-Rel. That is, a GAL4-Trip6 fusion protein can activate transcription in yeast and chicken cells, Trip6 can enable C-terminal sequences of v-Rel to activate transcription in yeast, and Trip6 can enhance activation by v-Rel from a kappaB site reporter plasmid in yeast. Although full-length Trip6 localizes to adhesion plaques, deletion of N-terminal sequences allows human Trip6 to enter the nucleus of chicken cells. Lastly, Northern blotting shows that Trip6 mRNA is expressed in many human tissues. Coexpression of Trip6 does not affect the transforming activity of v-Rel. Taken together, our results indicate that Trip6 may be a protein that is important for the ability of v-Rel to activate transcription and transform cells, and may represent a potential target for blocking Rel-mediated oncogenesis and transcriptional activation.
Indexed as
Identifiers
10794523PMC6157364W2412868519What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.